Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer

BACKGROUND: There are no randomized control trials (RCTs) comparing gemcitabine and nab-paclitaxel (Gem-Nab) and fluorouracil, folinic acid, irinotecan, oxaliplatin (FOLFIRINOX) for advanced pancreatic cancer (APC). Although it is well known that RCT-based efficacy often does not translate to real-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Arciero, Vanessa, Luo, Jin, Parmar, Ambica, Dai, Wei Fang, Beca, Jaclyn M, Raphael, Michael J, Isaranuwatchai, Wanrudee, Habbous, Steven, Tadrous, Mina, Earle, Craig C, Biagi, Jim J, Mittmann, Nicole, Arias, Jessica, Gavura, Scott, Chan, Kelvin K W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346632/
https://www.ncbi.nlm.nih.gov/pubmed/35758620
http://dx.doi.org/10.1093/jncics/pkac047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346632/
https://www.ncbi.nlm.nih.gov/pubmed/35758620
http://dx.doi.org/10.1093/jncics/pkac047

Ejemplares similares